Randomized, Double-Blind, Placebo Controlled Phase II Study of FOLFOX +/- Ziv-Aflibercept in Patients With Advanced Esophageal and Gastric Cancer
Phase of Trial: Phase II
Latest Information Update: 26 Mar 2019
Price : $35 *
At a glance
- Drugs Aflibercept (Primary) ; Fluorouracil; Folinic acid; Oxaliplatin
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- Acronyms ZAMEGA
- 26 Mar 2019 Results assessing efficacy of mFOLFOX6 and Ziv-Aflibercept in patients with first-line metastatic gastroesopheageal adenocarcinoma published in the Cancer
- 26 Mar 2019 Primary endpoint (6-month Progression-free Survival (PFS)) has not been met published in the Cancer.
- 05 Apr 2018 Status changed from active, no longer recruiting to completed.